{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/expediting-regulatory-submission-supporting-biotech-milestones-infant-gene-therapy-1#webpage",
"url": "https://www.fortrea.com/insights/expediting-regulatory-submission-supporting-biotech-milestones-infant-gene-therapy-1",
"name": "Expediting regulatory submission: Supporting biotech milestones in infant gene therapy trials",
"description": "This Fortrea case study explores gene therapy clinical trials in a complex infant study, highlighting the critical role of regulatory strategy, accelerated approvals, and precise execution in achieving key clinical and regulatory milestones. Gene therapy development in rare pediatric populations requires careful planning, alignment with global health authorities, and robust clinical trial design to ensure safety, efficacy, and compliance. The case study demonstrates how strategic regulatory engagement, efficient clinical trial management, and cross-functional coordination enabled timely progression through critical milestones, supporting successful advancement in a highly specialized therapeutic area. By addressing the unique challenges of infant gene therapy clinical trials, including patient safety considerations, ethical requirements, and operational complexity, this approach underscores how integrated clinical and regulatory expertise can drive successful outcomes in advanced therapy development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Expediting regulatory submission: Supporting biotech milestones in infant gene therapy trials",
"item": "https://www.fortrea.com/insights/expediting-regulatory-submission-supporting-biotech-milestones-infant-gene-therapy-1"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/expediting-regulatory-submission-supporting-biotech-milestones-infant-gene-therapy-1#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/expediting-regulatory-submission-supporting-biotech-milestones-infant-gene-therapy-1#webpage"
},
"headline": "Gene Therapy Clinical Trials | Regulatory Milestones in Infant Study | Fortrea Case Study",
"description": "This Fortrea case study explores gene therapy clinical trials in a complex infant study, highlighting the critical role of regulatory strategy, accelerated approvals, and precise execution in achieving key clinical and regulatory milestones. Gene therapy development in rare pediatric populations requires careful planning, alignment with global health authorities, and robust clinical trial design to ensure safety, efficacy, and compliance. The case study demonstrates how strategic regulatory engagement, efficient clinical trial management, and cross-functional coordination enabled timely progression through critical milestones, supporting successful advancement in a highly specialized therapeutic area. By addressing the unique challenges of infant gene therapy clinical trials, including patient safety considerations, ethical requirements, and operational complexity, this approach underscores how integrated clinical and regulatory expertise can drive successful outcomes in advanced therapy development.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-09/infant-gene-therapy-reg-submission.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-09-04",
"dateModified": "2025-09-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-09/case-study-infant-gene-therapy-regulatory-milestones-0625.pdf",
"encodingFormat": "application/pdf"
}
}
]
}